Kyverna appoints Greg Martini as CFO; Marc Grasso transitions to strategic advisor

Kyverna Therapeutics, Inc.

Greg Martini named CFO effective May 18, 2026; previously CFO of Ironwood Pharmaceuticals.
Marc Grasso steps down as CFO, stays as strategic advisor through Aug 1, 2026 for transition.
Compensation: $525K salary, 40% bonus target, $300K sign-on bonus, 325K stock option (4-year vest).
Company advancing miv-cel (KYV-101) toward potential first approval in stiff person syndrome.
Option grant of 325K shares as inducement under Nasdaq Rule 5635(c)(4); exercise price May 18 close.

item 5.02item 8.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gregory Martini

Chief Financial Officer

KYTX · Kyverna Therapeutics, Inc.

Effective: 2026-05-18
Filed: May 18, 2026 12:00 UTC

On May 14, 2026, the Board of Directors (the “Board”) of Kyverna Therapeutics, Inc. (the “Company”) appointed Gregory Martini as the Company’s Chief Financial Officer, effective May 18, 2026 (the “Effective Date”).

Source: SEC EDGAR

accession 0001193125-26-227920

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.